Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer

S Watanabe, K Nakagawa, K Suzuki… - Japanese journal of …, 2017 - academic.oup.com
The treatments for advanced non-small cell lung cancer (NSCLC) should control both local
and microscopic systemic disease, because the 5-year survival of patients with Stage III …
被引用次数：78 相关文章

Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer

SI Watanabe, K Nakagawa, K Suzuki… - … journal of clinical …, 2017 - pubmed.ncbi.nlm.nih.gov
The treatments for advanced non-small cell lung cancer (NSCLC) should control both local
and microscopic systemic disease, because the 5-year survival of patients with Stage III …

Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer

S Watanabe, K Nakagawa, K Suzuki… - Japanese Journal of …, 2017 - academic.oup.com
The treatments for advanced non-small cell lung cancer (NSCLC) should control both local
and microscopic systemic disease, because the 5-year survival of patients with Stage III …

[引用][C] Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer

S Watanabe, K Nakagawa, K Suzuki… - Japanese Journal of …, 2017 - cir.nii.ac.jp
Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …

Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer.

SI Watanabe, K Nakagawa, K Suzuki… - Japanese Journal of …, 2017 - europepmc.org
The treatments for advanced non-small cell lung cancer (NSCLC) should control both local
and microscopic systemic disease, because the 5-year survival of patients with Stage III …

Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer.

S Watanabe, K Nakagawa, K Suzuki… - … Journal of Clinical …, 2017 - search.ebscohost.com
The treatments for advanced non-small cell lung cancer (NSCLC) should control both local
and microscopic systemic disease, because the 5-year survival of patients with Stage III …